## Life-Saving Care for Patients with End-Stage Kidney Disease during the War in Ukraine 2022

<table>
<thead>
<tr>
<th>Journal:</th>
<th>Clinical Journal of the American Society of Nephrology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manuscript ID</td>
<td>CJASN-0472-04-22.R1</td>
</tr>
<tr>
<td>Manuscript Type:</td>
<td>Unsolicited Features</td>
</tr>
<tr>
<td>Date Submitted by the Author:</td>
<td>04-May-2022</td>
</tr>
<tr>
<td>Complete List of Authors:</td>
<td>Stepanova, Natalia; SI Institute of Nephrology of the National Academy of Medical Sciences of Ukraine, Head of Nephrology and Dialysis Department; Ukrainian Association of Nephrologists and Kidney Transplant Specialists, Vice-President Kolesnyk, Mykola; SI Institute of Nephrology of the National Academy of Medical Sciences of Ukraine, Director; Ukrainian Association of Nephrologists and Kidney Transplant Specialists, President Mithani, Zain; University of Miami Katz Family Division of Nephrology and Hypertension, Assistant Professor of Medicine Alkofair, Baneen; University of Miami Miller School of Medicine, Department of Public Health Sciences Shakour, Rebecca; University of Miami Miller School of Medicine Petrova, Anna; Bogomolets National Medical University, Nephrologist, Department of Internal Medicine, ISN Young Nephrologists Committee Novakivskyv, Volodymyr; Fresenius Medical Care Ukraine LLC, Medical Director Hymes, Jeffrey; Fresenius Medical Care North America, Global Head of Clinical Affairs, Chief Medical Officer, Care Delivery Chair, Pharmacy &amp; Therapeutics Committee EVP Brzosko, Szymon; DaVita Poland, Chief Medical Officer; Medical University of Bialystok, Associate Professor, 1st Department of Nephrology and Transplantation Giulian, Jeff; DaVita Inc, Chief Medical Officer Espinol, Zelde; Sylvester Comprehensive Cancer Center, Psychoncologist; University of Miami Miller School of Medicine, Assistant Professor, Department of Psychiatry and Behavioral Sciences Shultz, James; P3H: Protect &amp; Promote Population Health in Complex Crises, Director; University of Miami Miller School of Medicine</td>
</tr>
<tr>
<td>Keywords:</td>
<td>kidney disease, hemodialysis, Equity, Epidemiology and outcomes, end stage kidney disease, end-stage renal disease, Disparity, dialysis, COVID-19, Ukraine</td>
</tr>
</tbody>
</table>
**Authors:** Stepanova, Natalia; Kolesnyk, Mykola; Mithani, Zain; Alkofair, Baneen; Shakour, Rebecca; Petrova, Anna; Novakivskyy, Volodymyr; Hymes, Jeffrey; Brzosko, Szymon; Giullian, Jeff; Espinel, Zelde; Shultz, James

**Title:** Life-Saving Care for Patients with End-Stage Kidney Disease during the War in Ukraine 2022

**Running head:** ESKD Care during 2022 Ukraine Invasion

**Manuscript Type:** Unsolicited Features

**Manuscript Category:** Perspectives Perspectives

**Funders:** FUNDREF :No data available.

**Financial Disclosure:** CUST_FINANCIAL_DISCLOSURE_-_FEATURES :No data available.

S. Brzosko reports employment with DaVita Poland.

J. Giullian reports employment with DaVita, Inc., ownership interest in DaVita, Inc., and serving on the Board of Directors of Nephrosant, INC. and on the Editorial Board of Nephrology News and Insights.

J.L. Hymes reports employment with Fresenius Medical Care North America; ownership interest in Davita, Fresenius Medical Care, and Nephroceuticals; and other interests or relationships with KCP.

M. Kolesnyk reports employment with the Institute of Nephrology of the National Academy of Science of Ukraine and serving as a member of ERA.

Z. Mithani reports serving as a board member of the Florida Society of Nephrology.

V. Novakivskyy reports employment with FMC Ukraine.

J.M. Shultz reports royalties from Springer Publishing Company.

N. Stepanova reports employment with and serving in an advisory or leadership role for Medical center LLC â€œNephrocenter.â€

The remaining authors have nothing to disclose.

**Total number of words:** 1493

**Abstract:** DOCUMENT_ABSTRACT :No data available.
Life-Saving Care for Patients with End-Stage Kidney Disease during the War in Ukraine 2022

Natalia Stepanova, Mykola Kolesnyk, Zain Mithani, Baneen Alkofair, Rebecca Lauren Shakour, Anna Petrova, Volodymyr Novakivskyy, Jeffrey L. Hymes, Szymon Brzosko, Jeff Giulian, Zelde Espinel, James M. Shultz

Natalia Stepanova MD, PhD, Prof
Head of Nephrology and Dialysis Department
State Institution “Institute of Nephrology
National Academy of Medical Science of Ukraine”
Vice-President, Ukrainian Association of Nephrologists and Kidney Transplant Specialists
Kyiv, Ukraine
+38 044 225 93 77
nmstep88@gmail.com

Mykola Kolesnyk MD, PhD, Prof
Director, State Institution “Institute of Nephrology
National Academy of Medical Science of Ukraine”
President, Ukrainian Association of Nephrologists and Kidney Transplant Specialists
Kyiv, Ukraine
director@inephrology.kiev.ua

Zain Mithani MD (corresponding author)
Assistant Professor of Medicine
Katz Family Division of Nephrology and Hypertension
University of Miami Miller School of Medicine
Don Soffer Clinical Research Center Room 815
1120 NW 14 St.
Miami, Florida 33136
305-243-3583
zmithani@med.miami.edu

Baneen Alkofair MD MPH
Department of Public Health Sciences
University of Miami Miller School of Medicine
Miami, Florida 33136
bxa570@med.miami.edu

Rebecca Lauren Shakour
University of Miami Miller School of Medicine
Miami, Florida 33136
610-392-2769
rebeccashakour@med.miami.edu

Anna Petrova, MD PhD
Nephrologist
Department of Internal Medicine
ISN Young Nephrologists Committee
Bogomolets National Medical University
Kyiv, Ukraine
anna2311doc@ukr.net

Volodymyr Novakivskyy MD, PhD
Medical Director, Fresenius Medical Care Ukraine
Cherkasy, Ukraine
volodymyr.novakivskyy@fmc-ag.com

Jeffrey L. Hymes MD
Global Head of Clinical Affairs
Chief Medical Officer, Care Delivery
Chair, Pharmacy & Therapeutics Committee
EVP, Fresenius Medical Care
Jeffrey.HymesMD@freseniusmedicalcare.com

Szymon Brzosko, MD, PhD
Chief Medical Officer, DaVita Poland
Wroclaw, Poland
Associate Professor
1st Department of Nephrology and Transplantation
Medical University of Bialystok,
Bialystok, Poland
szymon.brzosko@davita.com

Jeff Giulian MD
Chief Medical Officer
DaVita, Inc.
jeffrey.giullian@davita.com

Zelde Espinel MD MA MPH
Assistant Professor
Department of Psychiatry and Behavioral Sciences
Psycho-oncologist, Sylvester Comprehensive Cancer Center
University of Miami Miller School of Medicine
1121 NW 14th Street
Miami, Florida 33136
305-243-4276
z.espinel@miami.edu

James M. Shultz MS PhD
Associate Professor
Director, P3H: Protect & Promote Population Health in Complex Crises
Department of Public Health Sciences
University of Miami Miller School of Medicine
Don Soffer Clinical Research Center Room 1507
1120 NW 14 St.
Miami, Florida 33136
305-243-6288
jshultz1@med.miami.edu
The health and survival of patients living with end stage kidney disease (ESKD) have been threatened by the ongoing conflict in Ukraine. Commencing February 24, 2022, the Russian invasion scaled up to become the largest and most ferocious military assault in Europe since World War 2. The war triggered forced migration, leading to the displacement of more than 13.3 million Ukrainians, equivalent to 32% of the nation’s 44.1 million citizens. This figure included 5.6 million refugees who fled to European nations and 7.7 million internally displaced persons inside Ukraine as of May 3, 2022. Estimates from Ukrainian officials place future refugee numbers—persons living outside Ukraine—in the range of 10 million.

Risks for kidney patients in wartime
Ukraine’s medically vulnerable patients, persons living with disabling medical conditions that require specialized care and customized approaches to safeguarding them from harm, have been incommensurately affected by the war. Among these are more than 11,000 patients who receive kidney replacement therapy (KRT). More than 1,500 have received kidney transplants, 6,000 depend upon hemodialysis, 2,700 receive hemodiafiltration, and almost 1,000 receive peritoneal dialysis (PD).

In peacetime, optimizing the health of patients on KRT requires frequent laboratory monitoring, provision of immunosuppressants, care for vascular or PD access, management of anemia with erythropoiesis stimulating agents, and iron supplementation and care of mineral bone disease. In consultation with their nephrologists, patients select the most appropriate form of KRT and identify accessible dialysis centers in their communities. However, in the context of ongoing hostilities, the reliance of these patients on multiple weekly visits to a hemodialysis center jeopardizes their survival.

In addition to Russia’s bombardment of civilian residences and neighborhoods, leading to mass displacement, the World Health Organization’s Surveillance System for Attacks on Health Care enumerated 186 attacks on health facilities—including dialysis centers—and on their patients, healthcare personnel, ambulances, and medical warehouses stocking PD supplies through May 3, 2022.

Dangers faced by Ukrainian patients receiving KRT
The safety and clinical disposition of Ukrainian patients receiving KRT vary by geographic region amid the dynamically changing conflict. First, some patients live in portions of Eastern Ukraine that were seized at the outset of the war and came under Russian control; unfortunately, these patients’ access to
kidney care and vital supplies cannot be controlled by the Ukrainian healthcare system. Second, other patients live in communities experiencing heavy bombardment and disruption of infrastructure, while lacking reliable humanitarian corridors for evacuation. In Mariupol, Volnovakha, Chernihiv, Bucha, Irpin, and many other cities and towns under siege, patients were cut off from hemodialysis services while experiencing power outages during bitterly cold weather, severe food shortages, and lack of one of the most essential necessities for kidney patients—ample supplies of clean water. The devastating bombardment of Mariupol deprived hemodialysis patients from accessing their clinics; one patient who successfully evacuated Mariupol reported that 49 of 50 patients at his center had died.

Third, some patients requiring KRT are among the 7.7 million internally displaced persons who evacuated their home communities but still reside inside Ukraine. Numerous dialysis centers were deployed in areas that were less frequently under attack to provide free hemodialysis services. Courageous nephrologists and staff remained in their clinics, sometimes moving dialysis equipment into basements, to continue treating their patients. Austere living conditions experienced by displaced patients on KRT, some of whom were actually living in the dialysis centers, prompted some patients to return to liberated home communities or travel abroad.

Fourth, fortunately, patients receiving KRT have been prioritized for immigration into European Union (EU) countries, including Poland, Romania, Slovakia, France, Germany, Italy, and the Republic of Moldova where they were able to resume regular hemodialysis treatments. Fifth, medical trauma sustained by civilians during bombardment, and military personnel engaged in battle, is creating a growing cohort of individuals who will require dialysis or transplant due to war-related acute kidney injury.

**Support for Ukrainian patients on KRT inside Ukraine and evacuated to Europe**

During the first two months of the war, an unknown number of Ukrainian patients receiving KRT were able to reach the relative safety of western Ukraine and neighboring EU countries. The receiving countries have generously supported special needs patients. For example, Poland, the nation that has received 3.1 million Ukrainian citizens, announced that refugees requiring medical support would be treated in accordance with the rules that apply to its own citizens. For example, costs for dialysis services for Polish citizens are reimbursed by the Polish National Health Fund; this funding was extended
to cover Ukrainian refugees on KRT who require dialysis. Poland also provides COVID-19 vaccination to refugees upon entry.

International organizations providing kidney care services with an established presence in Europe have been instrumental in providing dialysis services for Ukrainian refugees requiring KRT as they arrive in EU countries. These private providers have been handling about two-thirds of refugee patients receiving KRT and the public sector has signaled its willingness to further assist these patients. As of mid-April, kidney care providers estimated that about 200 Ukrainian kidney patients on KRT were receiving regular dialysis treatments in Poland.

In addition to providing direct dialysis services for Ukrainian refugees in receiving countries, international organizations providing kidney care services have shipped supplies to dialysis centers that are still operating inside Ukraine. For example, one private dialysis service provided sufficient materials for 6,000 treatments to clinics in Lviv and Rivne.

More broadly, The European Kidney Health Alliance drafted an open letter regarding what the world nephrology community can do to protect Ukrainian patients on KRT including: providing reliable life-saving therapies, rapidly training relevant healthcare professionals, enhancing telemedicine capabilities, assuring free access to care in refugee-receiving countries, and facilitating air transport.8

**Superimposed risks from COVID-19**

For patients on KRT currently living in war-torn communities inside Ukraine, or attempting a life-saving migratory journey to a border nation, overt threats to health and life are vividly evident. Less outwardly visible are the ubiquitous risks posed by the ongoing COVID-19 pandemic.

First, persons living with chronic kidney disease who receive KRT are at elevated risk for COVID-19 infection and progression to severe or fatal disease.9 Second, COVID-19 rates in Ukraine were moderately high when the war began, and the highly transmissible Omicron variant (and extremely infectious BA.2 Omicron sub-lineage) was predominating throughout the first months of the war. Third, COVID-19 vaccination rates in Ukraine were extremely low. Less than 35% of the population had received the 2-dose regimen, while only 1.6% had received a “booster” dose that is much more protective against severe disease caused by Omicron. Fourth, behavioral mitigation strategies, including
wearing masks, physically distancing, and limiting the size of gatherings, were unfeasible during the conflict. Fifth, individuals on KRT shared bomb shelters during air raids, packed trains while evacuating, and jammed reception centers when arriving in receiving countries. In all instances, these patients could not avoid sharing the airspace and the respiratory aerosols produced by those around them, thereby elevating their risks for contracting COVID-19.

**Mental health considerations**

For persons living with chronic kidney disease, mental health impacts are multi-layered. First, patients receiving KRT grapple daily with their medical condition. Lifestyles are transformed and revolve around the imperative to receive dialysis or immunosuppressant therapies multiple times weekly. Psychosocial stressors associated with their diagnosis, the rigors of treatment, and shortened life expectancy, exert a toll on mental wellness. Being diagnosed with chronic kidney diseases increases the incidence of common mental disorders, most notably major depression, anxiety disorders, and posttraumatic stress disorder.

Second, the COVID-19 pandemic produced a global upsurge in the prevalence of mental disorders. With baseline rates of psychopathology elevated worldwide due to COVID-19, the add-on stressors of living with chronic kidney diseases are more likely to significantly impair function.10

Third, the inescapable exposures to the hazards of war, and the constancy of being under attack, amplify the intensity of the life stressors just described—living with chronic kidney disease during the COVID-19 pandemic. The entire population of Ukraine has experienced repetitive, potentially traumatizing exposures to the horrors of war. Many Ukrainian citizens have experienced direct threats to their own lives, physical injury during the bombardment, or loss of a loved one. Displacement from home and community, experienced by more than 3 of 10 Ukrainians, is associated with compounding losses of property, possessions, identity, and social support.

One other element of the Russian assault is riveting in its psychological power and significance: these continuing deadly fusillades are perpetrated acts of mass violence.

In conclusion, Ukrainian citizens living with end-stage kidney disease, are challenged in their abilities to cope simultaneously with their diagnosis, the pandemic, and the war. They are attempting to do so
while access to their life-saving treatments, care providers, and support networks are disrupted. Nonetheless, all Ukrainians, including nephrologists and their patients, stand together with their army, fearlessly fighting for the independence of Ukraine. Among them, there are many volunteers, including those traveling abroad for the sole purpose of getting a kidney transplant and returning to the front. Ukrainian nephrologists endure the cruel war with, and for, their patients.
Disclosures:

S. Brzosko reports employment with DaVita Poland.

J. Giullian reports employment with DaVita, Inc., ownership interest in DaVita, Inc., and serving on the Board of Directors of Nephrosant, INC. and on the Editorial Board of Nephrology News and Insights.

J.L. Hymes reports employment with Fresenius Medical Care North America; ownership interest in Davita, Fresenius Medical Care, and Nephroceuticals; and other interests or relationships with KCP.

M. Kolesnyk reports employment with the Institute of Nephrology of the National Academy of Science of Ukraine and serving as a member of ERA.

Z. Mithani reports serving as a board member of the Florida Society of Nephrology.

V. Novakivskyy reports employment with FMC Ukraine.

J.M. Shultz reports royalties from Springer Publishing Company.

N. Stepanova reports employment with and serving in an advisory or leadership role for Medical center LLC “Nephrocenter.”

The remaining authors have nothing to disclose.

Funding: None.

Acknowledgments: The content of this article reflects the personal experience and views of the author(s) and should not be considered medical advice or recommendation. The content does not reflect the views or opinions of the American Society of Nephrology (ASN) or CJASN. Responsibility for the information and views expressed herein lies entirely with the author(s).

Author Contributions:

Baneen Alkofair: Conceptualization, Data curation, Writing – review & editing

Szymon Brzosko: Data curation, Writing – review & editing

Zelde Espinel: Writing – review & editing

Jeff Giullian: Conceptualization, Writing – review & editing

Jeffrey L. Hymes: Conceptualization, Data curation, Resources, Writing – review & editing

Mykola Kolesnyk: Conceptualization, Data curation, Writing – review & editing

Zain Mithani: Conceptualization, Formal analysis, Writing – original draft, Writing – review & editing

Volodymyr Novakivskyy: Conceptualization, Data curation, Writing – review & editing
References


